News EyePoint Pharmaceuticals Reports Positive Masked Safety Update for Lead Product Candidate EYP-1901 in Ongoing PAVIA and DAVIO 2 Phase 2 Clinical Trials as of September 1, 2023 Staff September 11, 2023 Iframe sync Post navigation Previous: Madrigal Pharmaceuticals Appoints Bill Sibold as Chief Executive OfficerNext: Veru Reports Clinical Data from the Discontinued ARTEST Study of Enobosarm, Novel Selective Androgen Receptor Targeting Agonist, in AR+ ER+ HER2- Metastatic Breast Cancer More Stories Clinical Trial Healthcare News Patient Care Pharmaceutical After Trump’s Marijuana Executive Order, Will the DEA Face a Court Imposed Deadline from MMJ’s Writ of Mandamus? Staff December 20, 2025 Healthcare News Pharmaceutical Black Book Research Releases Its 2026 Annual Methodology and Governance Statement for Healthcare IT Vendor Rankings Staff December 20, 2025 Healthcare News Pharmaceutical Black Book Research Releases Its 2026 Annual Methodology and Governance Statement for Healthcare IT Vendor Rankings Staff December 20, 2025
